| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 67 | 2025 | 113 | 12.510 |
Why?
|
| Lung Diseases, Interstitial | 58 | 2025 | 149 | 11.010 |
Why?
|
| Pulmonary Fibrosis | 44 | 2025 | 109 | 10.260 |
Why?
|
| Lung | 87 | 2025 | 1490 | 5.530 |
Why?
|
| Arthritis, Rheumatoid | 23 | 2024 | 261 | 4.970 |
Why?
|
| Syndecan-2 | 6 | 2022 | 14 | 2.750 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 23 | 2024 | 604 | 2.390 |
Why?
|
| Lung Injury | 8 | 2024 | 121 | 2.260 |
Why?
|
| Tomography, X-Ray Computed | 39 | 2025 | 2093 | 2.180 |
Why?
|
| Bleomycin | 22 | 2024 | 152 | 1.980 |
Why?
|
| Fibroblasts | 24 | 2025 | 878 | 1.910 |
Why?
|
| Lung Transplantation | 18 | 2023 | 323 | 1.820 |
Why?
|
| Pulmonary Emphysema | 12 | 2023 | 93 | 1.760 |
Why?
|
| Biomarkers | 31 | 2025 | 3105 | 1.590 |
Why?
|
| Lymphangioleiomyomatosis | 10 | 2023 | 16 | 1.540 |
Why?
|
| Smoking | 20 | 2024 | 1049 | 1.450 |
Why?
|
| Humans | 205 | 2025 | 125025 | 1.340 |
Why?
|
| Single-Cell Analysis | 7 | 2024 | 291 | 1.310 |
Why?
|
| Indoles | 5 | 2025 | 191 | 1.310 |
Why?
|
| Lung Diseases | 10 | 2025 | 385 | 1.310 |
Why?
|
| Alveolar Epithelial Cells | 8 | 2025 | 34 | 1.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 509 | 1.230 |
Why?
|
| Radiation Injuries | 2 | 2022 | 143 | 1.230 |
Why?
|
| Mucin-5B | 10 | 2024 | 12 | 1.140 |
Why?
|
| Mice | 53 | 2025 | 17711 | 0.890 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 42 | 0.890 |
Why?
|
| Vital Capacity | 8 | 2024 | 76 | 0.880 |
Why?
|
| Animals | 65 | 2025 | 34205 | 0.880 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2024 | 129 | 0.870 |
Why?
|
| Disease Progression | 16 | 2024 | 2083 | 0.870 |
Why?
|
| Silicosis | 1 | 2023 | 4 | 0.850 |
Why?
|
| Middle Aged | 71 | 2025 | 26670 | 0.840 |
Why?
|
| Pyridones | 4 | 2023 | 118 | 0.830 |
Why?
|
| MicroRNAs | 6 | 2025 | 858 | 0.810 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2013 | 77 | 0.800 |
Why?
|
| Aged | 57 | 2025 | 19653 | 0.800 |
Why?
|
| Primary Graft Dysfunction | 5 | 2023 | 25 | 0.800 |
Why?
|
| Telomere | 7 | 2024 | 218 | 0.800 |
Why?
|
| Male | 94 | 2025 | 61429 | 0.800 |
Why?
|
| Idiopathic Interstitial Pneumonias | 3 | 2024 | 9 | 0.770 |
Why?
|
| Cryopreservation | 2 | 2020 | 73 | 0.770 |
Why?
|
| Endothelial Cells | 11 | 2023 | 505 | 0.770 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2019 | 120 | 0.760 |
Why?
|
| Gene Expression Profiling | 12 | 2024 | 1757 | 0.760 |
Why?
|
| Mice, Inbred C57BL | 24 | 2025 | 4415 | 0.760 |
Why?
|
| Carbon Monoxide | 3 | 2019 | 29 | 0.760 |
Why?
|
| Female | 97 | 2025 | 66669 | 0.750 |
Why?
|
| Antimetabolites | 1 | 2021 | 33 | 0.740 |
Why?
|
| Pulmonologists | 2 | 2021 | 4 | 0.720 |
Why?
|
| Proteomics | 8 | 2025 | 506 | 0.700 |
Why?
|
| Forced Expiratory Volume | 6 | 2018 | 171 | 0.690 |
Why?
|
| Respiratory Function Tests | 15 | 2021 | 198 | 0.680 |
Why?
|
| Matrix Metalloproteinase 7 | 4 | 2016 | 21 | 0.670 |
Why?
|
| Emphysema | 4 | 2023 | 67 | 0.670 |
Why?
|
| Fibrosis | 10 | 2024 | 442 | 0.660 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 1653 | 0.660 |
Why?
|
| Palmitic Acid | 1 | 2019 | 34 | 0.660 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 51 | 0.640 |
Why?
|
| Hospitalization | 2 | 2025 | 1783 | 0.630 |
Why?
|
| Hyaluronic Acid | 5 | 2021 | 96 | 0.620 |
Why?
|
| Epithelial Cells | 9 | 2023 | 907 | 0.610 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2022 | 339 | 0.600 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2016 | 114 | 0.600 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 209 | 0.580 |
Why?
|
| Scleroderma, Systemic | 4 | 2024 | 107 | 0.580 |
Why?
|
| Macrophages, Alveolar | 4 | 2020 | 49 | 0.560 |
Why?
|
| Smoke | 2 | 2016 | 61 | 0.540 |
Why?
|
| Inflammasomes | 2 | 2016 | 151 | 0.540 |
Why?
|
| Antiviral Agents | 2 | 2021 | 766 | 0.540 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 304 | 0.530 |
Why?
|
| Critical Illness | 1 | 2021 | 599 | 0.530 |
Why?
|
| Hermanski-Pudlak Syndrome | 5 | 2022 | 8 | 0.530 |
Why?
|
| Autophagy | 6 | 2023 | 395 | 0.530 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 3 | 2022 | 10 | 0.530 |
Why?
|
| Aging | 3 | 2024 | 1180 | 0.520 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 587 | 0.520 |
Why?
|
| RNA | 1 | 2020 | 573 | 0.510 |
Why?
|
| Polymorphism, Genetic | 6 | 2017 | 818 | 0.510 |
Why?
|
| Severity of Illness Index | 11 | 2025 | 2905 | 0.510 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 43 | 0.500 |
Why?
|
| Sirolimus | 4 | 2019 | 227 | 0.490 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 49 | 0.490 |
Why?
|
| Bronchoalveolar Lavage Fluid | 11 | 2021 | 149 | 0.490 |
Why?
|
| Pollen | 1 | 2015 | 46 | 0.480 |
Why?
|
| Graft Rejection | 6 | 2021 | 588 | 0.480 |
Why?
|
| Blood Proteins | 4 | 2025 | 124 | 0.470 |
Why?
|
| Adult | 36 | 2025 | 29452 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2022 | 493 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 543 | 0.460 |
Why?
|
| Cohort Studies | 19 | 2025 | 4819 | 0.450 |
Why?
|
| Transforming Growth Factor beta | 6 | 2022 | 465 | 0.440 |
Why?
|
| Pulmonary Alveoli | 8 | 2022 | 134 | 0.440 |
Why?
|
| Air Pollutants | 1 | 2015 | 102 | 0.440 |
Why?
|
| Signal Transduction | 13 | 2023 | 4595 | 0.430 |
Why?
|
| Pericytes | 1 | 2013 | 21 | 0.430 |
Why?
|
| Double-Blind Method | 7 | 2025 | 1605 | 0.430 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 2413 | 0.420 |
Why?
|
| Allergens | 1 | 2015 | 252 | 0.420 |
Why?
|
| Smokers | 5 | 2023 | 40 | 0.420 |
Why?
|
| Gene Expression Regulation | 9 | 2022 | 2525 | 0.410 |
Why?
|
| A549 Cells | 3 | 2024 | 44 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2024 | 3175 | 0.410 |
Why?
|
| Congresses as Topic | 1 | 2014 | 174 | 0.410 |
Why?
|
| Lymphangiogenesis | 4 | 2020 | 18 | 0.400 |
Why?
|
| Myofibroblasts | 3 | 2024 | 77 | 0.400 |
Why?
|
| Prognosis | 11 | 2023 | 4683 | 0.400 |
Why?
|
| Primary Prevention | 1 | 2014 | 172 | 0.400 |
Why?
|
| Mitochondria | 6 | 2023 | 677 | 0.400 |
Why?
|
| Transcriptome | 4 | 2024 | 978 | 0.390 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2021 | 128 | 0.380 |
Why?
|
| Citrullination | 2 | 2022 | 6 | 0.380 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 372 | 0.380 |
Why?
|
| Hypertension, Pulmonary | 6 | 2020 | 439 | 0.370 |
Why?
|
| Respiratory Mucosa | 3 | 2021 | 91 | 0.360 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 5167 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 361 | 0.360 |
Why?
|
| Aged, 80 and over | 13 | 2025 | 6535 | 0.360 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 49 | 0.360 |
Why?
|
| Virus Internalization | 2 | 2021 | 55 | 0.360 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2016 | 37 | 0.340 |
Why?
|
| Cells, Cultured | 10 | 2025 | 3017 | 0.340 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2019 | 560 | 0.340 |
Why?
|
| Cellular Senescence | 3 | 2021 | 163 | 0.340 |
Why?
|
| Macrophages | 5 | 2023 | 626 | 0.330 |
Why?
|
| Phosphoproteins | 3 | 2018 | 419 | 0.330 |
Why?
|
| Vesicular Transport Proteins | 3 | 2020 | 120 | 0.330 |
Why?
|
| Trophoblasts | 2 | 2021 | 113 | 0.320 |
Why?
|
| Up-Regulation | 6 | 2019 | 874 | 0.320 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2014 | 24 | 0.320 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2018 | 561 | 0.320 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 3 | 2025 | 9 | 0.320 |
Why?
|
| Risk Factors | 16 | 2024 | 10278 | 0.320 |
Why?
|
| Matrix Metalloproteinases, Secreted | 2 | 2023 | 4 | 0.310 |
Why?
|
| Gene Expression | 2 | 2020 | 1550 | 0.310 |
Why?
|
| Immunomodulation | 2 | 2021 | 79 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor D | 4 | 2017 | 6 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 325 | 0.300 |
Why?
|
| Autoantibodies | 4 | 2024 | 424 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2022 | 157 | 0.300 |
Why?
|
| Homeostasis | 6 | 2023 | 704 | 0.290 |
Why?
|
| Extracellular Matrix | 3 | 2025 | 239 | 0.290 |
Why?
|
| Hydroxychloroquine | 2 | 2018 | 17 | 0.290 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2023 | 361 | 0.290 |
Why?
|
| Inflammation | 5 | 2021 | 1447 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2018 | 7 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 1337 | 0.280 |
Why?
|
| Transplant Recipients | 3 | 2019 | 218 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2021 | 1016 | 0.270 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 4405 | 0.270 |
Why?
|
| Gene Regulatory Networks | 2 | 2022 | 365 | 0.260 |
Why?
|
| In Vitro Techniques | 2 | 2021 | 968 | 0.260 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2377 | 0.260 |
Why?
|
| Telomerase | 4 | 2020 | 169 | 0.250 |
Why?
|
| Cell Differentiation | 5 | 2025 | 1908 | 0.250 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1701 | 0.250 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2024 | 114 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2020 | 825 | 0.240 |
Why?
|
| Chronic Disease | 5 | 2021 | 1187 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2021 | 436 | 0.240 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2019 | 1033 | 0.240 |
Why?
|
| Protein Kinases | 2 | 2018 | 329 | 0.240 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2017 | 40 | 0.240 |
Why?
|
| Stem Cells | 3 | 2021 | 710 | 0.240 |
Why?
|
| Prospective Studies | 9 | 2022 | 6122 | 0.240 |
Why?
|
| Galectin 3 | 2 | 2016 | 36 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2022 | 12269 | 0.230 |
Why?
|
| Apoptosis | 5 | 2019 | 1819 | 0.230 |
Why?
|
| Case-Control Studies | 10 | 2021 | 3310 | 0.230 |
Why?
|
| Gene Silencing | 3 | 2021 | 241 | 0.230 |
Why?
|
| Methylmalonic Acid | 1 | 2024 | 15 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 1150 | 0.220 |
Why?
|
| United States | 13 | 2024 | 10884 | 0.220 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 125 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2021 | 493 | 0.220 |
Why?
|
| Fatigue | 1 | 2025 | 188 | 0.220 |
Why?
|
| Precision Medicine | 2 | 2024 | 321 | 0.210 |
Why?
|
| Niacin | 1 | 2023 | 58 | 0.210 |
Why?
|
| Citrulline | 2 | 2016 | 111 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 585 | 0.210 |
Why?
|
| Cell Movement | 4 | 2024 | 850 | 0.210 |
Why?
|
| Immunoglobulin A | 2 | 2023 | 207 | 0.210 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 1694 | 0.210 |
Why?
|
| Sarcoidosis | 1 | 2023 | 61 | 0.200 |
Why?
|
| Macular Degeneration | 1 | 2024 | 115 | 0.200 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 163 | 0.200 |
Why?
|
| Cluster Analysis | 2 | 2022 | 402 | 0.200 |
Why?
|
| Hospital Mortality | 2 | 2021 | 1027 | 0.200 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 114 | 0.200 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 114 | 0.200 |
Why?
|
| Collagen | 2 | 2022 | 317 | 0.200 |
Why?
|
| Genomics | 2 | 2024 | 1520 | 0.200 |
Why?
|
| Synovial Membrane | 1 | 2022 | 27 | 0.200 |
Why?
|
| Mammals | 2 | 2022 | 254 | 0.200 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2022 | 4 | 0.190 |
Why?
|
| Retrospective Studies | 18 | 2024 | 16334 | 0.190 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 645 | 0.190 |
Why?
|
| beta Catenin | 2 | 2023 | 215 | 0.190 |
Why?
|
| DNA | 2 | 2018 | 1606 | 0.190 |
Why?
|
| Sp1 Transcription Factor | 1 | 2022 | 42 | 0.190 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 120 | 0.190 |
Why?
|
| Rituximab | 2 | 2024 | 152 | 0.190 |
Why?
|
| Machine Learning | 1 | 2024 | 250 | 0.190 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 235 | 0.190 |
Why?
|
| Elastic Tissue | 1 | 2021 | 19 | 0.190 |
Why?
|
| Lymphatic Vessels | 3 | 2019 | 37 | 0.180 |
Why?
|
| Chemokine CXCL10 | 3 | 2022 | 53 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 42 | 0.180 |
Why?
|
| Veterans | 2 | 2023 | 1715 | 0.180 |
Why?
|
| Genetic Markers | 4 | 2019 | 605 | 0.180 |
Why?
|
| Family | 2 | 2025 | 562 | 0.180 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 473 | 0.180 |
Why?
|
| Immunologic Factors | 2 | 2024 | 173 | 0.180 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2021 | 2 | 0.180 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2021 | 2 | 0.180 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 103 | 0.180 |
Why?
|
| Respiratory System Abnormalities | 1 | 2021 | 42 | 0.180 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 86 | 0.180 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 18 | 0.180 |
Why?
|
| Alanine | 1 | 2021 | 187 | 0.180 |
Why?
|
| Viral Load | 1 | 2023 | 389 | 0.180 |
Why?
|
| Desmoplakins | 1 | 2020 | 10 | 0.180 |
Why?
|
| Phenotype | 5 | 2022 | 4266 | 0.180 |
Why?
|
| Airway Resistance | 1 | 2020 | 36 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2022 | 154 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 396 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 46 | 0.180 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 1361 | 0.180 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 64 | 0.170 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 180 | 0.170 |
Why?
|
| Prevalence | 8 | 2024 | 2458 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2019 | 587 | 0.170 |
Why?
|
| Spirometry | 5 | 2021 | 73 | 0.170 |
Why?
|
| Celecoxib | 1 | 2020 | 32 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 703 | 0.170 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2020 | 57 | 0.170 |
Why?
|
| Cell Survival | 2 | 2020 | 819 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2020 | 97 | 0.170 |
Why?
|
| ROC Curve | 3 | 2017 | 571 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2021 | 335 | 0.160 |
Why?
|
| CD36 Antigens | 1 | 2019 | 38 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2025 | 641 | 0.160 |
Why?
|
| DNA Damage | 2 | 2013 | 515 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1320 | 0.160 |
Why?
|
| Syntenins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hexosaminidases | 1 | 2019 | 7 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 552 | 0.160 |
Why?
|
| Smad7 Protein | 1 | 2019 | 5 | 0.160 |
Why?
|
| Polyamines | 1 | 2019 | 27 | 0.160 |
Why?
|
| Endostatins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2017 | 3422 | 0.160 |
Why?
|
| Myositis | 2 | 2018 | 61 | 0.160 |
Why?
|
| Bone Marrow | 3 | 2018 | 323 | 0.160 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2019 | 23 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2017 | 471 | 0.160 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 55 | 0.160 |
Why?
|
| Tissue Donors | 3 | 2017 | 483 | 0.160 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 299 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2021 | 462 | 0.150 |
Why?
|
| Pneumonia | 1 | 2022 | 325 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 486 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 253 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 274 | 0.150 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 17 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 139 | 0.150 |
Why?
|
| Interleukin-8 | 2 | 2022 | 210 | 0.150 |
Why?
|
| Collagen Type III | 1 | 2018 | 22 | 0.150 |
Why?
|
| Total Lung Capacity | 3 | 2015 | 12 | 0.150 |
Why?
|
| Laminin | 1 | 2018 | 69 | 0.150 |
Why?
|
| Triglycerides | 1 | 2021 | 571 | 0.150 |
Why?
|
| Cell Line | 6 | 2021 | 2717 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2024 | 238 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2024 | 516 | 0.150 |
Why?
|
| Connectome | 1 | 2019 | 104 | 0.140 |
Why?
|
| Carboxyhemoglobin | 1 | 2017 | 10 | 0.140 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 2054 | 0.140 |
Why?
|
| Allografts | 4 | 2021 | 176 | 0.140 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 108 | 0.140 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 24 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 259 | 0.140 |
Why?
|
| Survival Rate | 6 | 2019 | 2051 | 0.140 |
Why?
|
| Mice, Knockout | 4 | 2021 | 3753 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2016 | 158 | 0.140 |
Why?
|
| Fibrinogen | 1 | 2018 | 156 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1399 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2017 | 47 | 0.140 |
Why?
|
| Thorax | 1 | 2018 | 73 | 0.140 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 53 | 0.140 |
Why?
|
| Age Factors | 4 | 2019 | 2815 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 75 | 0.140 |
Why?
|
| Tuberous Sclerosis | 2 | 2019 | 121 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2021 | 543 | 0.140 |
Why?
|
| Carrier Proteins | 2 | 2013 | 1027 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 342 | 0.140 |
Why?
|
| Photopheresis | 1 | 2017 | 3 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2021 | 781 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2017 | 72 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 625 | 0.140 |
Why?
|
| Syk Kinase | 1 | 2017 | 16 | 0.140 |
Why?
|
| Parenchymal Tissue | 1 | 2016 | 2 | 0.140 |
Why?
|
| Protein-Arginine Deiminases | 3 | 2023 | 6 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 483 | 0.130 |
Why?
|
| Alemtuzumab | 1 | 2017 | 86 | 0.130 |
Why?
|
| Regression Analysis | 4 | 2024 | 776 | 0.130 |
Why?
|
| Instillation, Drug | 1 | 2016 | 7 | 0.130 |
Why?
|
| Microbiota | 1 | 2021 | 384 | 0.130 |
Why?
|
| Protein Unfolding | 1 | 2016 | 10 | 0.130 |
Why?
|
| Osteopontin | 1 | 2016 | 49 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 2019 | 664 | 0.130 |
Why?
|
| Immunoproteins | 1 | 2016 | 2 | 0.130 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 178 | 0.130 |
Why?
|
| Glucose | 1 | 2021 | 876 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 2654 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 238 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 27 | 0.130 |
Why?
|
| Interleukin-18 | 1 | 2016 | 61 | 0.130 |
Why?
|
| Taste | 1 | 2016 | 32 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2013 | 22 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 223 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 59 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 9 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 164 | 0.130 |
Why?
|
| Magnoliopsida | 1 | 2015 | 4 | 0.130 |
Why?
|
| Embolism, Fat | 1 | 2015 | 6 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 4 | 0.120 |
Why?
|
| Urbanization | 1 | 2015 | 7 | 0.120 |
Why?
|
| Young Adult | 6 | 2024 | 9054 | 0.120 |
Why?
|
| Cities | 1 | 2015 | 47 | 0.120 |
Why?
|
| Sulfur | 1 | 2015 | 13 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 47 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 104 | 0.120 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2015 | 5 | 0.120 |
Why?
|
| Transplants | 1 | 2015 | 34 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2017 | 191 | 0.120 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2015 | 6 | 0.120 |
Why?
|
| Mexico | 1 | 2015 | 181 | 0.120 |
Why?
|
| Everolimus | 1 | 2015 | 50 | 0.120 |
Why?
|
| Logistic Models | 5 | 2019 | 1800 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 783 | 0.120 |
Why?
|
| Radiation Pneumonitis | 1 | 2014 | 12 | 0.120 |
Why?
|
| Lipids | 1 | 2018 | 519 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 69 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2014 | 22 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 292 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 89 | 0.120 |
Why?
|
| Temperature | 1 | 2015 | 303 | 0.120 |
Why?
|
| Chemokines | 1 | 2015 | 134 | 0.120 |
Why?
|
| Phospholipases A2 | 1 | 2014 | 36 | 0.120 |
Why?
|
| Drug Approval | 1 | 2015 | 43 | 0.120 |
Why?
|
| Epitopes | 1 | 2016 | 432 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2017 | 3044 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 1275 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 673 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 151 | 0.110 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2015 | 319 | 0.110 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 9 | 0.110 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2014 | 15 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 766 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 150 | 0.110 |
Why?
|
| Linear Models | 4 | 2019 | 681 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 2876 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1893 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 138 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2020 | 1505 | 0.110 |
Why?
|
| Seasons | 1 | 2015 | 312 | 0.110 |
Why?
|
| Hydroxyproline | 1 | 2013 | 7 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 86 | 0.110 |
Why?
|
| Adipocytes | 1 | 2014 | 141 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2013 | 48 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 474 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 296 | 0.110 |
Why?
|
| Asthma | 1 | 2021 | 756 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 623 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 249 | 0.110 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 137 | 0.110 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 274 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2019 | 1496 | 0.100 |
Why?
|
| Transplantation | 1 | 2013 | 27 | 0.100 |
Why?
|
| Antibodies | 1 | 2014 | 367 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 382 | 0.100 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2012 | 18 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 532 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 212 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 109 | 0.100 |
Why?
|
| Mutation | 6 | 2017 | 5897 | 0.100 |
Why?
|
| Pancytopenia | 1 | 2012 | 41 | 0.100 |
Why?
|
| Biopsy | 3 | 2015 | 1242 | 0.100 |
Why?
|
| Incidence | 5 | 2019 | 3130 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 55 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 155 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1984 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 228 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 42 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 84 | 0.090 |
Why?
|
| Time Factors | 5 | 2021 | 6296 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 77 | 0.090 |
Why?
|
| Genotype | 4 | 2018 | 2569 | 0.090 |
Why?
|
| Telomere Shortening | 2 | 2024 | 33 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2013 | 218 | 0.090 |
Why?
|
| Organ Specificity | 2 | 2021 | 426 | 0.080 |
Why?
|
| Protein Binding | 3 | 2020 | 1747 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2018 | 1252 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 2009 | 27 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2009 | 43 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2010 | 121 | 0.080 |
Why?
|
| Syndecan-1 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2022 | 46 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2024 | 623 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1534 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 150 | 0.080 |
Why?
|
| Iceland | 2 | 2019 | 11 | 0.080 |
Why?
|
| Clinical Enzyme Tests | 1 | 2008 | 16 | 0.070 |
Why?
|
| Methotrexate | 2 | 2021 | 336 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2014 | 818 | 0.070 |
Why?
|
| Liver | 1 | 2015 | 1747 | 0.070 |
Why?
|
| Peptides | 2 | 2024 | 812 | 0.070 |
Why?
|
| Proteins | 2 | 2023 | 1037 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 670 | 0.070 |
Why?
|
| RNA Stability | 1 | 2007 | 84 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 668 | 0.060 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 437 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 3674 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2023 | 505 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1714 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 729 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 236 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1425 | 0.060 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2025 | 5 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2813 | 0.060 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2025 | 27 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 887 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 651 | 0.060 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 63 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 700 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 407 | 0.060 |
Why?
|
| Monocytes | 2 | 2023 | 345 | 0.060 |
Why?
|
| Basigin | 1 | 2024 | 14 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 730 | 0.060 |
Why?
|
| Acetylation | 1 | 2025 | 167 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2024 | 49 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 273 | 0.060 |
Why?
|
| Lakes | 1 | 2024 | 3 | 0.060 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2024 | 97 | 0.060 |
Why?
|
| Stress Fibers | 1 | 2023 | 4 | 0.060 |
Why?
|
| Neutrophils | 2 | 2021 | 378 | 0.050 |
Why?
|
| Acetate-CoA Ligase | 1 | 2023 | 4 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 495 | 0.050 |
Why?
|
| Acetyl Coenzyme A | 1 | 2023 | 13 | 0.050 |
Why?
|
| Niacinamide | 1 | 2023 | 23 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 210 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1684 | 0.050 |
Why?
|
| Acute Disease | 2 | 2018 | 1095 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2016 | 404 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 335 | 0.050 |
Why?
|
| Pedigree | 2 | 2021 | 1610 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2023 | 68 | 0.050 |
Why?
|
| Professional Practice Gaps | 1 | 2023 | 15 | 0.050 |
Why?
|
| Chaperonin Containing TCP-1 | 1 | 2023 | 9 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2024 | 145 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2024 | 84 | 0.050 |
Why?
|
| Fenbendazole | 1 | 2022 | 2 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2015 | 357 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 212 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 235 | 0.050 |
Why?
|
| Registries | 2 | 2020 | 1434 | 0.050 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Actins | 1 | 2025 | 338 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 49 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 170 | 0.050 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2022 | 3 | 0.050 |
Why?
|
| Albinism | 1 | 2022 | 8 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 256 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 21 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2022 | 17 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2022 | 53 | 0.050 |
Why?
|
| src-Family Kinases | 1 | 2022 | 91 | 0.050 |
Why?
|
| Organoids | 1 | 2025 | 269 | 0.050 |
Why?
|
| Losartan | 1 | 2022 | 34 | 0.050 |
Why?
|
| Adolescent | 2 | 2017 | 19412 | 0.050 |
Why?
|
| Regeneration | 1 | 2024 | 210 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 54 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 91 | 0.050 |
Why?
|
| Hemiterpenes | 1 | 2001 | 2 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2022 | 155 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2023 | 278 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 217 | 0.050 |
Why?
|
| Lung Diseases, Fungal | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histones | 1 | 2025 | 534 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1708 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 375 | 0.050 |
Why?
|
| Skin | 1 | 2024 | 519 | 0.050 |
Why?
|
| Ribotyping | 1 | 2021 | 50 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2021 | 11 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2015 | 801 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2021 | 62 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2021 | 69 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 64 | 0.040 |
Why?
|
| Radiologists | 1 | 2021 | 45 | 0.040 |
Why?
|
| Microcirculation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2021 | 121 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 89 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2022 | 302 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 101 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 170 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 184 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2021 | 122 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 97 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2022 | 246 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 43 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 442 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 192 | 0.040 |
Why?
|
| Activins | 1 | 2020 | 73 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1114 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 182 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2020 | 32 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 262 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 12 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 324 | 0.040 |
Why?
|
| Contraindications | 1 | 2000 | 78 | 0.040 |
Why?
|
| Software | 1 | 2024 | 687 | 0.040 |
Why?
|
| Semaphorins | 1 | 2019 | 29 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 87 | 0.040 |
Why?
|
| Zebrafish | 1 | 2022 | 380 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 297 | 0.040 |
Why?
|
| Biological Transport | 1 | 2020 | 352 | 0.040 |
Why?
|
| Alleles | 2 | 2017 | 1614 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 780 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 427 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 230 | 0.040 |
Why?
|
| Maleimides | 1 | 2019 | 11 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 645 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 295 | 0.040 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 162 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 556 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 107 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2019 | 58 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 549 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 57 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 386 | 0.040 |
Why?
|
| Genes | 1 | 2019 | 446 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 161 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 292 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 308 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 475 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 372 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2018 | 21 | 0.040 |
Why?
|
| Smad2 Protein | 1 | 2018 | 50 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2014 | 692 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 64 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 350 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 363 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 538 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 308 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2018 | 58 | 0.040 |
Why?
|
| Systems Biology | 1 | 2018 | 58 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 381 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 342 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 607 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 827 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 492 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 275 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2020 | 801 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 39 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1070 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2019 | 477 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2017 | 144 | 0.030 |
Why?
|
| Walk Test | 1 | 2017 | 24 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 172 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 109 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 343 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 621 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1021 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1006 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2019 | 383 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 2016 | 16 | 0.030 |
Why?
|
| Phagocytes | 1 | 2016 | 23 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 819 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2021 | 765 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 125 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 106 | 0.030 |
Why?
|
| Hydrolases | 1 | 2016 | 56 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1305 | 0.030 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 300 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 15 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 339 | 0.030 |
Why?
|
| Benzoates | 1 | 2015 | 21 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 105 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2014 | 1538 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2016 | 188 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 382 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2000 | 483 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 69 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 333 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2015 | 2603 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 100 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 48 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1242 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1633 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 163 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2000 | 495 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 192 | 0.030 |
Why?
|
| Angiomyolipoma | 1 | 2014 | 4 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 278 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 315 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 66 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 42 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1158 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 92 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1112 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 283 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 465 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 2014 | 12 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 256 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 60 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 174 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2016 | 244 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2016 | 407 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 126 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 80 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 239 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 230 | 0.030 |
Why?
|
| China | 1 | 2015 | 246 | 0.030 |
Why?
|
| Galectins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 64 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 299 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2014 | 201 | 0.030 |
Why?
|
| Mucin-1 | 1 | 2014 | 35 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 914 | 0.030 |
Why?
|
| Arginine | 1 | 2016 | 334 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 780 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 728 | 0.030 |
Why?
|
| Radiography | 1 | 2016 | 802 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 368 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 106 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2013 | 2 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1237 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 700 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 998 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2015 | 362 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 211 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 7 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1095 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 367 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 199 | 0.020 |
Why?
|
| Sequestosome-1 Protein | 1 | 2012 | 12 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 168 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2012 | 74 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 556 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2368 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 147 | 0.020 |
Why?
|
| Fibronectins | 1 | 2012 | 110 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2012 | 102 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 43 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 351 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 1073 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 3723 | 0.020 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 166 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 151 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 226 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 693 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 306 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 210 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 38 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 325 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 243 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 84 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 254 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 350 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1065 | 0.020 |
Why?
|
| Schistosoma mansoni | 1 | 2010 | 24 | 0.020 |
Why?
|
| Schistosomiasis mansoni | 1 | 2010 | 24 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 216 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2010 | 97 | 0.020 |
Why?
|
| Signal Recognition Particle | 1 | 2009 | 9 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Polymyositis | 1 | 2009 | 7 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2011 | 455 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 1563 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 805 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 728 | 0.020 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2009 | 25 | 0.020 |
Why?
|
| Asbestos | 1 | 2008 | 13 | 0.020 |
Why?
|
| Health | 1 | 2009 | 37 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2009 | 36 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 617 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 589 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 859 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 174 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2008 | 58 | 0.020 |
Why?
|
| Carcinogens | 1 | 2008 | 149 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 181 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 212 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1907 | 0.020 |
Why?
|
| Transcription Factor TFIIH | 1 | 2007 | 5 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 471 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 263 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 434 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 457 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 1109 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1526 | 0.010 |
Why?
|
| Ethane | 1 | 2001 | 1 | 0.010 |
Why?
|
| Pentanes | 1 | 2001 | 1 | 0.010 |
Why?
|
| Acetone | 1 | 2001 | 2 | 0.010 |
Why?
|
| Sulfur Oxides | 1 | 2001 | 2 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 19 | 0.010 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 12 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 2790 | 0.010 |
Why?
|
| Breath Tests | 1 | 2001 | 178 | 0.010 |
Why?
|